Bfsg LLC Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Bfsg LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 115,507 shares of the company's stock after buying an additional 12,515 shares during the period. Novo Nordisk A/S comprises about 1.0% of Bfsg LLC's portfolio, making the stock its 24th biggest position. Bfsg LLC's holdings in Novo Nordisk A/S were worth $8,021,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Revolve Wealth Partners LLC raised its position in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock worth $214,000 after acquiring an additional 200 shares in the last quarter. Legacy Capital Wealth Partners LLC lifted its stake in shares of Novo Nordisk A/S by 10.4% in the 4th quarter. Legacy Capital Wealth Partners LLC now owns 5,337 shares of the company's stock valued at $459,000 after purchasing an additional 504 shares in the last quarter. Allworth Financial LP raised its holdings in shares of Novo Nordisk A/S by 6.0% during the 4th quarter. Allworth Financial LP now owns 33,399 shares of the company's stock valued at $2,691,000 after buying an additional 1,897 shares during the period. Sheaff Brock Investment Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 16.1% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 4,027 shares of the company's stock valued at $346,000 after buying an additional 557 shares during the period. Finally, Valmark Advisers Inc. increased its holdings in Novo Nordisk A/S by 2.1% during the 4th quarter. Valmark Advisers Inc. now owns 6,627 shares of the company's stock worth $570,000 after purchasing an additional 136 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

NVO has been the subject of a number of research analyst reports. BNP Paribas initiated coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an "underperform" rating for the company. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday. Guggenheim lowered Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a report on Thursday, April 17th. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Finally, Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $112.00.

Novo Nordisk A/S Stock Down 3.5%

NYSE:NVO opened at $77.02 on Tuesday. The stock's fifty day simple moving average is $67.61 and its 200-day simple moving average is $79.24. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $345.62 billion, a P/E ratio of 23.41, a P/E/G ratio of 0.90 and a beta of 0.66. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. The business had revenue of $11.87 billion for the quarter. Equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.